Therma Bright, a company specializing in medical devices and technology, has announced that its AI-powered digital cough technology is being considered as a partner technology in a new chronic cough drug clinical trial. The technology, which analyzes cough sounds to identify patterns and trends, has the potential to revolutionize the way chronic cough is diagnosed and treated.
Chronic cough is a common symptom of many respiratory diseases, including asthma, bronchitis, and COPD. Current methods of diagnosing chronic cough are limited and often rely on subjective assessments by healthcare providers. Therma Bright’s digital cough technology aims to provide a more objective and accurate method of diagnosing chronic cough by analyzing the frequency and intensity of cough sounds.
The technology has already shown promising results in early testing, with a high level of accuracy in detecting cough patterns associated with respiratory diseases. By partnering with a new chronic cough drug clinical trial, Therma Bright hopes to further validate the effectiveness of its technology in diagnosing and monitoring chronic cough.
If successful, the technology could lead to significant improvements in the diagnosis and treatment of chronic cough, potentially reducing healthcare costs and improving patient outcomes. Therma Bright’s AI-powered digital cough technology has the potential to revolutionize the field of respiratory health and provide a much-needed solution for individuals suffering from chronic cough.
Overall, Therma Bright’s innovative approach to diagnosing chronic cough shows great promise in improving patient care and advancing medical technology. Stay tuned for more updates on the company’s partnership with the chronic cough drug clinical trial and the impact of its digital cough technology on the healthcare industry.
Source
Photo credit news.google.com